Lanthanum Carbonate Phosphate Binding for CKD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic kidney disease (CKD) and associated complications like hyperphosphatemia are limited to end-stage renal disease patients, and existing phosphate binders have limitations such as unmanageable dosing, hypercalcemia risks, and toxicity issues, leaving a need for effective treatments for earlier stages of CKD and related conditions like soft tissue calcification and secondary hyperparathyroidism.
Innovation Solution
Oral administration of a therapeutically effective amount of a non-toxic lanthanum compound, specifically lanthanum carbonate or lanthanum carbonate hydrate, to treat subjects with stage one to four CKD, soft tissue calcification, and secondary hyperparathyroidism, reducing phosphate absorption and associated abnormalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If calcium-based phosphate binders are used to control hyperphosphatemia in ESRD subjects, then phosphate levels are reduced, but hypercalcemia risks and soft tissue calcification occur
Solution Approach 1:
Lanthanum carbonate acts as an intermediary substance that binds phosphate in the gastrointestinal tract without releasing calcium into the bloodstream. This mediator approach allows phosphate removal while avoiding the calcium-mediated harmful effects of calcium-based binders, directly resolving the contradiction between phosphate control and hypercalcemia prevention
Solution Approach 2:
The invention extracts the phosphate-binding function from calcium-based systems and transfers it to lanthanum-based systems. By taking out the calcium component that causes hypercalcemia while retaining the phosphate-binding capability, the solution achieves phosphate control without the associated harmful effects
2Quantity of substance
If aluminum-based binders are used for phosphate control, then phosphate levels are effectively reduced, but central nervous system and bone toxicity occur with long-term use
Solution Approach 1:
Lanthanum carbonate functions as a disposable, non-accumulating phosphate binder that acts locally in the gastrointestinal tract. Unlike aluminum-based binders that accumulate in bone and brain tissue causing long-term toxicity, lanthanum is excreted in feces without significant systemic accumulation, providing effective phosphate control without progressive toxicity
Solution Approach 2:
Lanthanum serves as a safe intermediary substance that performs phosphate binding without the toxic accumulation properties of aluminum. It achieves the desired phosphate control function while avoiding the harmful long-term effects on the central nervous system and bone structure
3Quantity of substance
If sevelamer is prescribed to ESRD subjects, then phosphate binding is achieved, but pill burden becomes unmanageably large due to lack of potency
Solution Approach 1:
Lanthanum carbonate exhibits superior phosphate-binding potency compared to sevelamer, allowing effective phosphate control with smaller doses. This parameter change in binding efficiency directly reduces the number of pills required, transforming the unmanageable pill burden into a clinically acceptable regimen
Solution Approach 2:
Lanthanum carbonate provides concentrated phosphate-binding activity in each tablet, creating local quality superiority over sevelamer. This enhanced potency per unit allows for reduced dosing frequency and lower total pill burden while maintaining effective phosphate control
4Reliability
If phosphate binders are limited to ESRD subjects only, then treatment safety is maintained, but earlier stage CKD patients with hyperphosphatemia receive no effective treatment
Solution Approach 1:
Lanthanum carbonate provides universal phosphate-binding therapy applicable across multiple CKD stages (1-5), not just ESRD. This multi-functional adaptability allows safe and effective treatment of hyperphosphatemia in earlier CKD stages while maintaining the safety profile established for ESRD patients, expanding the therapeutic indication beyond the previous limitation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of lanthanum compounds effectively reduces serum phosphate levels, arrests the progression of CKD, and mitigates soft tissue calcification and secondary hyperparathyroidism, providing a manageable dosing regimen without toxicity or hypercalcemia risks.
Implementation Method 1
reduces phosphate absorption
Data Source
AI summary
A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRO), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. In a preferred embodiement, the composition contains lanthanum carbonate hydrate or lanthanum hydroxycarbonate. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.